Navigation Links
GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
Date:12/17/2008

ed pipeline of novel Toll-like Receptor (TLR) product candidates. Based on Dynavax's proprietary technology platform, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax's product programs are supported by global partnerships with leading pharmaceutical companies such as Merck & Co., Inc., GlaxoSmithKline, and AstraZeneca AB, as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health. For more information visit www.dynavax.com.

Dynavax Forward-Looking Statement

This press release contains "forward-looking statements," including statements related to the potential value of payments that may be received under our collaboration with GSK, the anticipated development of our inhibitors of endosomal TLRs, the future responsibilities of the parties under the collaboration agreement and Dynavax's ability to perform under the terms of the collaboration agreement. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including difficulties or delays in discovery or development, initiation and completion of preclinical or clinical studies, the results of those studies and the impact of those results on the initiation and completion of subsequent studies and issues arising in the regulatory process; achieving our GSK collaborative agreement objectives; our ability to obtain additional financing to support our operations; and other risks detailed in the "Risk Factors" section of our Quarterly Report on Form 10-Q. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

About GlaxoSmithKline

GlaxoSmithKline - one of the world's leadin
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
2. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
3. GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene
4. AUDIO from Medialink and GlaxoSmithKline: Give Kids A Boost For Their Health!
5. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
6. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
7. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
8. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
9. GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business
10. IADR and GlaxoSmithKline Consumer Healthcare announce winners
11. A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance :  – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases – 
(Date:9/17/2014)... (PRWEB) September 17, 2014 Fasoo ... Security Testing (SAST) tool, at AppSec USA 2014 in ... 9 am to 6 pm at booth G4 inside ... of the leading software security conferences for developers, auditors, ... tool that provides developers and managers with the ability ...
(Date:9/17/2014)... world-leading provider of scientific, technical and medical information ... a position statement by the European Menopause and ... on the topic of breast cancer screening. ... in women, with slightly more than ten percent ... is a well-established method to detect breast cancer. ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In ... Services, Inc.’s Drug Benefit News (DBN) continues to ... reported in its Aug. 8 issue , CVS ... exclusion lists for 2015 each cut more drugs ... much savings these exclusions are likely to achieve. ...
(Date:9/17/2014)... 17, 2014 In a continuing effort ... Nile virus threats, Mosquito Shield of the South Shore ... with the Hanover Youth Athletic Association to treat area ... daily practices going until dusk, prime mosquito feeding time, ... athletes, coaches, and parents involved in outdoor athletic activities. ...
(Date:9/17/2014)... 17, 2014 According to new ... the leading global authority in medical device market ... regeneration market is expected to exceed $3.7 ... breast reconstruction, hernia repair, dural repair, vaginal slings, ... dental soft tissue regeneration. , Approximately 300,000 ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 3
... March 10 Speaker Nancy Pelosi and Majority Whip James E. Clyburn held a photo opportunity this afternoon with representatives from the National Association of Public ... ... ... ...
... uncovered a mechanism for resistance to paclitaxel in ovarian ... chemotherapy resistance. Mohamed K. Hassan, Ph.D., a ... research as a collaborative study with his colleagues when ... in Egypt. Results of this study were presented at ...
... treating tumors with extreme heat or moderate heat may ... presented at the second AACR Dead Sea International Conference ... the Clinic, held March 7-10, 2010. "Low ... in curing both malignant and benign tumors using minimally ...
... , March 10 Omega Protein Corporation (NYSE: OME ), the nation,s leading producer of Omega-3 fish oil and specialty fish meal ... with net income of $12.6 million ( $0.69 per share) for the year ended December 31, 2008 . , ... ... ...
... 10 International Merchant Advisors, Inc. (PK: IMAI) ... announced today that the company is preparing to ... Organic Science, Inc.  Organic Science, Inc. is intended to become ... and is focused on the implementation of Organic,s  plans for ...
... March 10 As part of its continued focus on developing programs designed to meet employers, needs, Regence has acquired the assets of Kinetix Living Corp., ... ... , ... ...
Cached Medicine News:Health News:Pelosi Remarks at Photo Opportunity with the National Association of Public Hospitals 2Health News:Omega Protein Reports 2009 Results 2Health News:Omega Protein Reports 2009 Results 3Health News:Omega Protein Reports 2009 Results 4Health News:Omega Protein Reports 2009 Results 5Health News:Omega Protein Reports 2009 Results 6Health News:Omega Protein Reports 2009 Results 7Health News:Omega Protein Reports 2009 Results 8Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 2Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 3Health News:Regence Invests in Kinetix Living Corp. 2Health News:Regence Invests in Kinetix Living Corp. 3
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
... G rowth factor enhances ... stem cells , , BOSTON, July ... Boston have now laid the groundwork for regenerating heart tissue after a heart ... In the July 24 issue of Cell , they show that a ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
... The ThromCat™ System is the first thrombectomy ... strength and simplicity for the full range ... Heliflex™ technology, the new ThromCat™ System flushes, ... of 700 mmHg and incorporates advanced vessel-wall ...
... telescoping plate design integrates the ... and vertebral column spacer. This ... need for supplemental fixation while ... bone graft to be delivered ...
... Tendril ST leads are ... leads, designed to bring ... and flexibility to you ... pre-formed "J leads are ...
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
Medicine Products: